Weight loss predictability by plasma metabolic signatures in adults with obesity and morbid obesity of the DiOGenes study
Objective Aim is to predict successful weight loss by metabolic signatures at baseline and to identify which differences in metabolic status may underlie variations in weight loss success. Methods In DiOGenes, a randomized, controlled trial, weight loss was induced using a low‐calorie diet (800 kcal...
Saved in:
Published in | Obesity (Silver Spring, Md.) Vol. 24; no. 2; pp. 379 - 388 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.02.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
Aim is to predict successful weight loss by metabolic signatures at baseline and to identify which differences in metabolic status may underlie variations in weight loss success.
Methods
In DiOGenes, a randomized, controlled trial, weight loss was induced using a low‐calorie diet (800 kcal) for 8 weeks. Men (N = 236) and women (N = 431) as well as groups with overweight/obesity and morbid obesity were studied separately. The relation between the metabolic status before weight loss and weight loss was assessed by stepwise regression on multiple data sets, including anthropometric parameters, NMR‐based plasma metabolites, and LC‐MS‐based plasma lipid species.
Results
Maximally, 57% of the variation in weight loss success can be predicted by baseline parameters. The most powerful predictive models were obtained in subjects with morbid obesity. In these models, the metabolites most predictive for weight loss were acetoacetate, triacylglycerols, phosphatidylcholines, specific amino acids, and creatine and creatinine. This metabolic profile suggests that high energy metabolism activity results in higher amounts of weight loss.
Conclusions
Possible predictive (pre‐diet) markers were found for amount of weight loss for specific subgroups. |
---|---|
Bibliography: | The DiOGenes project is funded by a grant from the EU Food Quality and Safety Priority of the Sixth Framework Programme, contract no. FP6‐2005‐513946, and cofinanced by the Netherlands Metabolomics Centre (NMC) which is part of the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research. Clinical trial registration ClinicalTrials.gov identifier NCT00390637. Johanna H. M. Stroeve, Edoardo Saccenti, and Jildau Bouwman contributed equally to the study. The authors declared no conflict of interest. Disclosure Funding agencies WHMS and AA designed study protocol; AD, KS, JV, and TH conducted research; ES and AKS analyzed data and performed statistical analysis; JHMS, JB, WHMS, and BvO performed biological interpretation; JHMS, ES, and JB wrote the paper. All authors contributed to the draft paper. WHMS had primary responsibility for final content. All authors read and approved the final manuscript. Author contributions SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ISSN: | 1930-7381 1930-739X |
DOI: | 10.1002/oby.21361 |